AIF translocates to the nucleus upon treatment of cells with UCD38B.
Leonardo J. Leon
Nagarekha Pasupuleti
Fredric Gorin
Kermit L. Carraway III
10.1371/journal.pone.0063038.g009
https://plos.figshare.com/articles/figure/_AIF_translocates_to_the_nucleus_upon_treatment_of_cells_with_UCD38B_/694798
<p>(<b>A</b>) MDA-MB-231 cells were treated with 500 µM amiloride, or 250 µM UCD38B for 2 hours, and cells were fractionated into nuclear (N) and cytosolic (C) components. Fractions were immunoblotted for CREB and histone H3 as nuclear markers, GAPDH as a cytosolic marker, and AIF. (<b>B</b>) Bands from the blot depicted in (A) were digitally quantified, and the nuclear AIF as a fraction of the total AIF was plotted for each condition. (<b>C</b>) Cells were treated for 2 hours with DMSO control or 250 µM amiloride, UCD74A or UCD38B. Cells were then fixed and stained with DAPI to visualize the nucleus (blue) and antibodies to AIF (green), and examined by confocal fluorescence microscopy. Results depicted in each panel are representative of 2–3 independent experiments.</p>
2013-04-30 01:19:58
Biochemistry
drug discovery
Small molecules
Molecular cell biology
Cell death
Cell growth
Cellular stress responses
Obstetrics and gynecology
breast cancer
oncology
Cancer treatment
Chemotherapy and drug treatment
Cancers and neoplasms
Breast tumors
translocates
nucleus
cells